Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 3
1996 1
1998 1
1999 1
2001 3
2002 1
2003 2
2004 3
2005 1
2006 1
2007 1
2009 3
2010 3
2012 1
2013 1
2014 4
2015 2
2016 5
2017 1
2018 3
2020 5
2021 4
2022 3
2023 4
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. Kalinsky K, et al. Among authors: tiersten a. J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19. J Clin Oncol. 2023. PMID: 37207300 Clinical Trial.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. Ma CX, et al. Among authors: tiersten a. JAMA Oncol. 2024 Mar 1;10(3):362-371. doi: 10.1001/jamaoncol.2023.6038. JAMA Oncol. 2024. PMID: 38236590 Free PMC article. Clinical Trial.
High-dose chemotherapy for breast cancer: evolving data.
Antman K, Tiersten A. Antman K, et al. Among authors: tiersten a. Oncology (Williston Park). 1999 Sep;13(9):1215-9. Oncology (Williston Park). 1999. PMID: 10509318 Free article. Review. No abstract available.
Association of Insulin Resistance and Higher Oncotype DX™ Recurrence Score.
Gordon NT, Alberty-Oller JJ, Fei K, Greco G, Gallagher EJ, LeRoith D, Feldman SM, Killilea B, Boolbol SK, Choi L, Friedman N, Pilewskie M, Port E, Tiersten A, Bickell NA. Gordon NT, et al. Among authors: tiersten a. Ann Surg Oncol. 2021 Oct;28(11):5941-5947. doi: 10.1245/s10434-021-09748-8. Epub 2021 Apr 3. Ann Surg Oncol. 2021. PMID: 33813671
Novel breast cancer treatment leads to hyperglycaemia.
Bass IR, Tiersten A, Trlica K, Ryncarz A, Adler B, Gallagher EJ. Bass IR, et al. Among authors: tiersten a. Diabet Med. 2020 May;37(5):893-894. doi: 10.1111/dme.14281. Epub 2020 Mar 10. Diabet Med. 2020. PMID: 32096251 No abstract available.
Palliation of Ulcerative Breast Lesions with Radiation.
Vempati P, Knoll MA, Dharmarajan K, Green S, Tiersten A, Bakst RL. Vempati P, et al. Among authors: tiersten a. Anticancer Res. 2016 Sep;36(9):4701-5. doi: 10.21873/anticanres.11024. Anticancer Res. 2016. PMID: 27630316
62 results